# Corbin Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/corbin-therapeutics

- Industry: Biotechnology
- Headquarters: Quebec City, Canada
- Website: www.corbinthera.com
- Total disclosed funding: $0.8M
- Latest round: Seed (Jan 9, 2017)
- Investors on record: 1

## About

Corbin Therapeutics Inc. is a Canadian biotech firm focused on developing innovative therapies for unmet medical needs, leveraging advanced technologies to create effective solutions in the healthcare sector.Founded in 2016 and headquartered in Quebec City, Canada, Corbin Therapeutics Inc. specializes in biotechnology solutions. The company raised CAD 1 million in Seed funding from GeneChem in January 2017, which was the only deal reported. No changes in business strategy have been noted.Corbin Therapeutics Inc. offers a range of innovative therapeutic products designed to address specific medical needs within the healthcare market. Their solutions aim to enhance patient outcomes and streamline treatment processes. The company primarily serves healthcare providers in North America and Europe, ensuring their offerings meet the evolving demands of medical professionals and patients alike.Corbin Therapeutics Inc. generates revenue through strategic partnerships and collaborations with healthcare stakeholders. Their revenue model focuses on long-term agreements, allowing clients to gain access to their suite of therapeutic solutions and ongoing support. The company’s flagship products are central to its revenue generation strategy, appealing to both institutional healthcare providers and individual patients.Corbin Therapeutics Inc. plans to expand its product line with the development of new therapeutic solutions targeting specific medical applications, with anticipated launches in the next 18 months. The firm is also focused on entering new geographical markets, particularly in Europe and Asia, with expansion efforts slated for completion by the end of 2024. The recent CAD 1 million Seed funding will support these initiatives, enhancing R&D capabilities and facilitating market entry.

## Funding rounds

- Seed, Jan 9, 2017, $0.8M — GeneChem

## Investors

- GeneChem (https://capitalatlas.ai/funds/genechem) — Seed